-
Nona Biosciences Partners with OverT Bio to Develop Next-Generation Cell Therapies for Solid Tumors
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a partnership with US biotechnology company OverT Bio, Inc. to develop next-generation cell therapies targeting solid tumors. The collaboration will leverage Nona’s heavy-chain antibody (HCAb) Harbour Mice platform, with no financial specifics disclosed. Nona Bio’s HCAb…
-
Nona Biosciences Partners with Alkyon Therapeutics to Develop Next-Generation Immunotherapies
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic partnership with U.S. biotechnology company Alkyon Therapeutics, Inc. (AlkyonTx). The collaboration aims to develop next-generation immunotherapy and other targeted therapy applications, leveraging Nona’s proprietary Harbour Mice fully human antibody platform. The financial details of the…
-
Nona Biosciences and Umoja Biopharma Join Forces to Develop In Vivo CAR-T Therapies
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic collaboration with US-based Umoja Biopharma to co-develop multi-target antibody therapies. The partnership will leverage Nona’s proprietary fully human heavy chain only antibody (HCAb) technology to create innovative CAR-T cell therapy drug candidates generated in vivo.…
-
Nona Biosciences Partners with Alaya.bio to Revolutionize CAR-T Therapy Development
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a strategic cooperation agreement with Alaya.bio, a France-based polymer delivery platform company. This collaboration aims to harness their respective strengths to streamline the development, manufacturing, and administration of chimeric antigen receptor (CAR)-T therapies through precision targeting and…
-
AstraZeneca Partners with Nona Biosciences in Multimillion-Dollar Monoclonal Antibody Agreement
•
HBM Holdings Ltd’s (HKG: 2142) wholly-owned subsidiary, Nona Biosciences, has announced a significant licensing agreement with the UK pharmaceutical giant AstraZeneca. The deal revolves around a pre-clinical monoclonal antibody (mAb) program, marking a substantial step forward in the development of innovative therapies. Under the terms of the agreement, AstraZeneca will…
-
Seagen Inc. Acquires Global Rights to HBM9033 ADC in Deal with Nona Biosciences and Medilink Therapeutics
•
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), and Suzhou-based Medilink Therapeutics have jointly announced the licensing of their co-developed antibody-drug conjugate (ADC), HBM9033 (YL215), to Pfizer Inc.’s (NYSE: PFE) unit Seagen Inc. (NASDAQ: SGEN). According to the agreement, Seagen will secure global clinical development and commercialization rights…
-
Nona Biosciences Partners with Lycia Therapeutics to Advance LYTAC Platform for Novel Therapies
•
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has announced a collaboration with U.S.-based biotech firm Lycia Therapeutics. This partnership grants Lycia access to Nona’s proprietary lysosomal targeting chimeras (LYTACs) platform, aimed at discovering and developing first-in-class therapeutics that target and degrade extracellular and membrane-bound proteins for…
-
Nona Biosciences Partners with GeneQuantum Healthcare to Advance Drug Conjugate Discovery
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the Netherlands, the United States, and China, has entered into a partnership with China-based GeneQuantum Healthcare. The collaboration aims to integrate the core technology platforms and professional expertise of both companies to empower the early discovery…
-
Nona Biosciences and BeiGene Form Partnership to Advance Antibody Discovery
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with China-based BeiGene (NASDAQ: BGNE). The collaboration focuses on the field of antibody discovery, with the aim of leveraging Nona’s proprietary technology to enhance BeiGene’s research capabilities. Financial details of the agreement have not…
